Personal View: Low-dose Lung Radiotherapy for COVID-19 Pneumonia – The Atypical Science and the Unknown Collateral Consequence

Field	Value	Language
dc.contributor.author	Tharmalingam, H.	en
dc.contributor.author	Díez, P.	en
dc.contributor.author	Tsang, Y.	en
dc.contributor.author	Hawksley, A.	en
dc.contributor.author	Conibear, J.	en
dc.contributor.author	Thiruthaneeswaran, N.	en
dc.date.accessioned	2020-06-18
dc.date.available	2020-06-18
dc.date.issued	2020	en
dc.identifier.uri	https://hdl.handle.net/2123/22589
dc.description.abstract	The novel coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has had a devastating impact, with the number of deaths worldwide by June 2020 over 400 000. There are currently no proven, effective treatments, so there is an urgent need for clinical trials to test new therapeutic interventions that may be of benefit.	en
dc.language.iso	en	en
dc.rights	Other
dc.subject	COVID-19	en
dc.subject	Coronavirus	en
dc.title	Personal View: Low-dose Lung Radiotherapy for COVID-19 Pneumonia – The Atypical Science and the Unknown Collateral Consequence	en
dc.type	Article	en
dc.identifier.doi	10.1016/j.clon.2020.06.002
usyd.faculty	Faculty of Medicine and Health, Sydney Medical School	en

Associated file/s

There are no files associated with this item.